retatrutide phase 2 results obesity nejm 2023 🤔 Adults with type diabetes (T2D) and lose less weight on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today Retatrutide hits 28% weight loss

do not freeze the solution or use if it has been exposed to extreme temperatures

GLP-1 drugs can only be prescribed to people after meeting stringent regulatory standards set by agencies like the FDA

A brief word on retatrutide Its a triple agonist hitting GLP-1, GIP, and glucagon receptors and the glucagon component is what sets it apart

The range in clinical trials runs from about 25% to 40%, depending on the drug, dose, duration, and whether participants were exercising and eating adequate protein

Plaintiffs argue this is insufficient

Because both agents sit at the center of intense marketing and online discussion, it is worth having a disciplined framework for reading any comparison including this one